Edgar Filing: MERRIMACK PHARMACEUTICALS INC - Form 4

MERRIMACK P Form 4 February 10, 201		EUTICAL	S INC							
FORM 4		STATES					COMMISSIO		PPROVAL 3235-0287	
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940							Expires: Estimated burden hou response	Number: January 31	
(Print or Type Respo	nses)									
1. Name and Address of Reporting Person * Schoeberl Birgit M. (Last) (First) (Middle) C/O MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201			 Issuer Name and Ticker or Trading Symbol MERRIMACK PHARMACEUTICALS INC [MACK] Date of Earliest Transaction (Month/Day/Year) 02/08/2016 				5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner			
							X Officer (give title Other (specify below) below) Head of Discovery			
((Street)		4. If Amendment, Date Original Filed(Month/Day/Year)			ıl	 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person 			
CAMBRIDGE,	MA 02139							More than One R		
(City)	(State)	(Zip)	Tab	ole I - Non-l	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned	
	ansaction Date tth/Day/Year)	2A. Deema Execution any (Month/Da	Date, if	3. Transactio Code (Instr. 8) Code V	4. Securit mAcquired Disposed (Instr. 3, 4 Amount	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: Report or	a separate line	e for each cla	ass of sec	urities bene	Perso	ons who res	or indirectly. spond to the colle ained in this form		SEC 1474 (9-02)	

required to respond to the collection of required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

Reporting Owners

Edgar Filing: MERRIMACK PHARMACEUTICALS INC - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	TransactiorDerivative Code Securities		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 5.42	02/08/2016		A	125,000	<u>(1)</u>	02/07/2026	Common Stock	125,000	

Reporting Owners

Reporting Owner Name / Address		Relationships					
	Director	10% Owner	Officer	Other			
Schoeberl Birgit M. C/O MERRIMACK PHARMACEUTIC ONE KENDALL SQUARE, SUITE B7 CAMBRIDGE, MA 02139	· · · · · · · · · · · · · · · · · · ·			Head of Discovery			
Signatures							
/s/ Jeffrey A. Munsie, attorney-in-fact	02/10/2016	i					
**Signature of Reporting Person	Date						

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This option vests as to 1/12th of the total number of shares on 5/8/16 and an additional 1/12th of the total number of shares at the end of each successive three month period thereafter until 2/8/19.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.